Autres langues Akeso, Inc. BOERSE MUENCHEN

Actions

4RY

KYG0146B1032

Marché Fermé - BOERSE MUENCHEN Autres places de cotation 21:43:23 05/07/2024			Varia. 5j.	Varia. 1 janv.
4,58 ^EUR	+5,53 %		+1,33 %	-13,58 %

01/07	Akeso, Inc. annonce un changement d'administrateurs	CI
04/06	Akeso élargit le territoire de son accord de licence pour un médicament contre le cancer du poumon	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Akeso, Inc. Announces Change of Directors	01/07
Akeso Expands Territory of License Agreement for Lung Cancer Drug	04/06
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	03/06
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%	31/05
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)	31/05
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival	30/05
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	24/05
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	24/05
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection	24/05
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	24/04
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	24/04
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/03
Akeso to Raise Over HK$1 Billion Via Share Sale	22/03
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19/03
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	06/03
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	05/03
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	05/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Akeso, Inc. BOERSE MUENCHEN

Actions

4RY

KYG0146B1032

Autres langues

Filtres